tbuckley/cabot-search huggingface dataset:
Case 9-1980
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Erich K. Lang, Karl H. Proppe
Journal: New England Journal of Medicine (1980)

PRESENTATION OF CASEA 46-year-old woman was admitted to the hospital because of fever and abdominal pain.Except for mild hypertension she was well until five months previously, when her menses ceased. During the two months before admission she complained of hot flashes, sweats, and depression. Two weeks before entry suprapubic pain developed and radiated to the right lower abdominal quadrant and right flank and intermittently to the left lower quadrant; the pain was aggravated by walking. Fatigue, anorexia, and mild constipation occurred. For several days before entry she had fever and chills.There was no history of nausea, vomiting, . . .
PTH-060 The role of risk stratification in predicting inflammatory bowel disease patients that require tb prophylaxis prior to biologic therapy: Abstract PTH-060 Table 1
Authors: CD Tweed, PJ Patel, CF Pollock, R Ward, E Wood, N Thoua, G Bothamley
Journal: Gut (2015)

<h3>Introduction</h3> Inflammatory bowel disease (IBD) is frequently treated with tumour necrosis factor-alpha inhibitors (anti-TNF). This is associated with an increased risk for reactivation tuberculosis (TB) in those with latent tuberculosis infection (LTBI), which preventive therapy can reduce by 74%.<sup>1</sup>The British Thoracic Society (BTS) guidelines include tables calculating the risk of developing TB and need for prophylaxis.<sup>2</sup> <h3>Method</h3> We retrospectively reviewed clinic letters from 2010 to 2014 for IBD patients referred for anti-TNF screening at an East London hospital. Ethnicity, age, years in the UK, Tuberculin skin test (TST) result, interferon-gamma release assay (IGRA) result, and use of prophylaxis was recorded. Adjusted annual risk was calculated as per the BTS guidelines and patients labelled as “high risk” if prophylaxis was indicated. This was compared with the number that received prophylaxis after TB specialist assessment. <h3>Results</h3> Out of the 116 patients identified, 91% were prescribed immunosuppressants (e.g., prednisolone, azathioprine, mercaptopurine). 37 patients were classified “high risk” as per the BTS guidelines; however following TB specialist assessment only 9 patients received prophylaxis. 14 of the 116 patients demonstrated positive TST and/or IGRA, although none of the patients receiving anti-TNF therapy developed reactivation TB. 100% of Black African and Indian ethnicity were classified “high risk”, although at least 78% of people in these groups were UK residents for over 10 years. <h3>Conclusion</h3> The BTS guidelines did not accurately predict which patients would require preventive therapy in this cohort. Clinical assessment and immunological testing by a TB specialist reduced the number receiving preventive therapy, without increased rates of TB. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V <i>et al</i>. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumour necrosis factor antagonists. Arthritis Rheum 2005;52:1766–72 British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing <i>Mycobacterium tuberculosis</i>infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800–805
Abnormalities in biomarkers of mineral and bone metabolism in kidney donors
Authors: Bertram L. Kasiske, Rajiv Kumar, Paul L. Kimmel, Todd E. Pesavento, Roberto S. Kalil, Edward S. Kraus, Hamid Rabb, Andrew M. Posselt, Teresa L. Anderson-Haag, Michael W. Steffes, Ajay K. Israni, Jon J. Snyder, Ravinder J. Singh, Matthew R. Weir
Journal: Kidney International (2016)
Clinical Phenotype and Segregation of Mitochondrial 3243A&gt;G Mutation in 2 Pairs of Monozygotic Twins
Authors: Kengo Maeda, Hiromichi Kawai, Mitsuru Sanada, Tomoya Terashima, Nobuhiro Ogawa, Ryo Idehara, Tetsuya Makiishi, Hitoshi Yasuda, Shun-ichi Sato, Ken-ichi Hoshi, Hiroyuki Yahikozawa, Katsuji Nishi, Yasushi Itoh, Kazumasa Ogasawara, Kazuo Tomita, Hiroko P. Indo, Hideyuki J. Majima
Journal: JAMA Neurology (2016)

The regulatory factors explaining the wide spectrum of clinical phenotypes for mitochondrial 3243A>G mutation are not known. Crosstalk between nuclear genes and mitochondrial DNA might be one factor.In this case series, we compared 2 pairs of male twins with the mitochondrial 3243 A>G mutation and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome with a female control patient. One pair of monozygotic twins presented with diabetes and deafness in their 30s, stroke-like episodes in their 40s, and cardiac events and death in their 50s. Another pair of twins presented with deafness and stroke-like episodes in their 20s. The degree of heteroplasmy of 3243A>G mutation in the various tissues and organs was similar in the first pair of twins compared with the control patient.The clinical phenotype and segregation of mitochondrial 3243A>G mutation was similar in monozygotic twins. The onset age and distribution of the symptoms might be regulated by nuclear genes. Our findings might help to predict the clinical course of the surviving twins and afford an opportunity for therapy before the onset of mitochondrial disease, especially for monozygotic twins caused by nuclear transfer with a small amount of nuclear-donor mitochondrial DNA.
Catheptic Activities of the Nuclei of Normal, Regenerating, and Neoplastic Tissues of the Rat
Authors: Mary E. Maver, Antoinette E. Greco, Ebba Løvtrup, Albert J. Dalton
Journal: JNCI Journal of the National Cancer Institute (1952)

Journal Article Catheptic Activities of the Nuclei of Normal, Regenerating, and Neoplastic Tissues of the Rat Get access Mary E. Maver, Mary E. Maver Search for other works by this author on: Oxford Academic PubMed Google Scholar Antoinette E. Greco, Antoinette E. Greco Search for other works by this author on: Oxford Academic PubMed Google Scholar Ebba Løvtrup, Ebba Løvtrup Search for other works by this author on: Oxford Academic PubMed Google Scholar Albert J. Dalton Albert J. Dalton National Cancer Institute3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 3, December 1952, Pages 687–703, https://doi.org/10.1093/jnci/13.3.687 Published: 01 December 1952 Article history Received: 29 July 1952 Published: 01 December 1952
Rapid Response Systems 20 Years Later
Authors: Christopher P. Bonafide, Damian Roland, Patrick W. Brady
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)
Authors: Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar-Yang Chau, Jiamei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie Tung-Ping Poon, Kwang-Hyub Han, Won-Young Tak, Han Chu Lee, Tianqiang Song, Sasan Roayaie, Luigi Bolondi, Kwan Sik Lee, Masatoshi Makuuchi, Fabricio Souza, Marie-Aude Le Berre, Gerold Meinhardt, Josep M. Llovet
Journal: Journal of Clinical Oncology (2014)

4006^ Background: Sorafenib is a multikinase inhibitor with proven efficacy in unresectable HCC. We evaluated the efficacy and safety of adjuvant sorafenib for HCC. Methods: Patients who had undergone surgical resection or local ablation with curative intent and had an intermediate or high recurrence risk were eligible. Main inclusion criteria were Child-Pugh score 5–7, ECOG PS 0, and no residual disease confirmed by CT or MRI. Exclusion criteria included recurrent HCC, ascites, extrahepatic spread, macrovascular invasion, and prior systemic therapy for HCC. Patients were stratified by curative treatment, geographic region, recurrence risk, and Child-Pugh status and randomized 1:1 to treatment with sorafenib 400 mg orally twice a day or placebo for a maximum of 4 yrs. The primary endpoint was recurrence-free survival (RFS) by independent review. Secondary endpoints included time to recurrence (TTR) and overall survival (OS). Results: A total of 1114 patients were randomized (n=556 sorafenib; n=558 placebo). Baseline characteristics were balanced between groups. Median age was 59 yrs, 62% were Asian, 81% had resection, 97% were Child-Pugh A, and 46% had high recurrence risk. The analysis was based on a total of 464 RFS events. No differences in RFS, TTR, and OS were observed (Table). The sorafenib group had a shorter median treatment duration (12.5 vs 22.2 mos) and lower mean daily dose (578 vs 778 mg). Discontinuation rates with sorafenib were higher due to treatment-emergent adverse events (TEAE) (24% vs 7%) and consent withdrawal (17% vs 6%). Most common grade (Gr) 3–4 sorafenib TEAEs occurring more frequently vs placebo were hand-foot skin reaction (28%), hypertension (7%), and diarrhea (6%). Conclusions:The primary endpoint of the trial was not met. Adverse events are consistent with the known sorafenib safety profile and no new safety findings were observed. Clinical trial information: NCT00692770. Sorafenib Placebo Hazard Ratio (95% CI) P* Median, mos RFS 33.4 33.8 0.940 (0.780 – 1.134) 0.26 TTR 38.6 35.8 0.891 (0.735 – 1.081) 0.12 OS NR NR 0.995 (0.761 – 1.300) 0.48 TEAE, % All Gr 98 90 Serious 40 42 Gr 3–4 69 47 Gr 5 3 2 Drug-related, all Gr 94 46 Serious 9 3 Gr 5 <1 <1 *One sided; NR, not reached.
David Oliver: The forgotten problem of incontinence
Authors: David Oliver
Journal: BMJ (2016)

My local council has to find £18m (€22.3m; $24.7m) of savings by closing libraries, day centres, and public toilets.1 Residents have organised to keep one toilet open: they know its value.2 It’s happening throughout the United Kingdom: even in my native Manchester, which the council says is “a great place to grow old,”3 only one public toilet remains.4

We report isolation and loneliness as having the most impact on wellbeing as we age.5 Fear of incontinence can be a major factor in trapping people in their own homes.6 And incontinence is a …
Reticuloendothelial Saturation Dictates the Development of RBC Resistance to Antibody-Mediated Clearance Following Incompatible Transfusion
Authors: Connie M Arthur, Amanda Mener, Seema Patel, Lilian Cataldi Rodrigues, Carol Xue, Robert Sheppard Nickel, James C. Zimring, Jeanne E Hendrickson, Sean R. Stowell
Journal: Blood (2014)
Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine
Authors: Yuichi Maeda, Takashi Kurakawa, Eiji Umemoto, Daisuke Motooka, Yoshinaga Ito, Kazuyoshi Gotoh, Keiji Hirota, Masato Matsushita, Yoki Furuta, Masashi Narazaki, Noriko Sakaguchi, Hisako Kayama, Shota Nakamura, Tetsuya Iida, Yukihiko Saeki, Atsushi Kumanogoh, Shimon Sakaguchi, Kiyoshi Takeda
Journal: Arthritis & Rheumatology (2016)

Objective The intestinal microbiota is involved in the pathogenesis of arthritis. Altered microbiota composition has been demonstrated in patients with rheumatoid arthritis (RA). However, it remains unclear how dysbiosis contributes to the development of arthritis. The aim of this study was to investigate whether altered composition of human intestinal microbiota in RA patients contributes to the development of arthritis. Methods We analyzed the fecal microbiota of patients with early RA and healthy controls, using 16S ribosomal RNA−based deep sequencing. We inoculated fecal samples from RA patients and healthy controls into germ‐free arthritis‐prone SKG mice and evaluated the immune responses. We also analyzed whether the lymphocytes of SKG mice harboring microbiota from RA patients react with the arthritis‐related autoantigen 60S ribosomal protein L23a (RPL23A). Results A subpopulation of patients with early RA harbored intestinal microbiota dominated by Prevotella copri ; SKG mice harboring microbiota from RA patients had an increased number of intestinal Th17 cells and developed severe arthritis when treated with zymosan. Lymphocytes in regional lymph nodes and the colon, but not the spleen, of these mice showed enhanced interleukin‐17 (IL‐17) responses to RPL23A. Naive SKG mouse T cells cocultured with P copri −stimulated dendritic cells produced IL‐17 in response to RPL23A and rapidly induced arthritis. Conclusion We demonstrated that dysbiosis increases sensitivity to arthritis via activation of autoreactive T cells in the intestine. Autoreactive SKG mouse T cells are activated by dysbiotic microbiota in the intestine, causing joint inflammation. Dysbiosis is an environmental factor that triggers arthritis development in genetically susceptible mice.
TCD in Infants: A Report from the BABY HUG Trial.
Authors: Robert J. Adams, Julio Barredo, Duane R. Bonds, Clark Brown, James Casella, Li Daner, A.Russell Gerber, Rathi Iyer, Judy Luden, Scott Miller, Caterina Minniti, Sohail Rana, Renee Rees, Zora Rogers, Stuart Toledano, Winfred Wang, Russell Ware, Sherri Zimmerman
Journal: Blood (2005)
P-162 Is Resection the Only Choice for the Treatment of Bilobar Colorectal Cancer Metastases?
Authors: A. Chiappa, E. Bertani, A. Zbar, F. Luca, G. Zampino Maria, N. Fazio, S. Ravenda Paola, M. Venturino, F. Orsi, C. Ferrari, I. Monsellato, R. Biffi
Journal: Annals of Oncology (2016)
Increasing the impact of medical image computing using community-based open-access hackathons: The NA-MIC and 3D Slicer experience
Authors: Tina Kapur, Steve Pieper, Andriy Fedorov, J-C Fillion-Robin, Michael Halle, Lauren O'Donnell, Andras Lasso, Tamas Ungi, Csaba Pinter, Julien Finet, Sonia Pujol, Jayender Jagadeesan, Junichi Tokuda, Isaiah Norton, Raul San Jose Estepar, David Gering, Hugo J.W.L. Aerts, Marianna Jakab, Nobuhiko Hata, Luiz Ibanez, Daniel Blezek, Jim Miller, Stephen Aylward, W. Eric L Grimson, Gabor Fichtinger, William M Wells, William E. Lorensen, Will Schroeder, Ron Kikinis
Journal: Medical Image Analysis (2016)
Case 38-1975
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Simeon Locke, Stanley J. Robboy
Journal: New England Journal of Medicine (1975)

Presentation of Case First admission. A seven-and-a-half-year-old girl was admitted to the hospital because of diabetes insipidus and short stature.She was born of a normal pregnancy and delivery, weighing 3.27 kg (25th percentile). Her initial physical development was considered normal, and she was well until 18 months of age, when there was a brief episode of high fever and delirium, without convulsions. At the age of two years her parents noticed that she was not growing; her height was in the 10th percentile, and her weight less than the 10th percentile. At about that time polydipsia and polyuria . . .
Case 52-1981
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Hugh F. Biller, Ben Z. Pilch
Journal: New England Journal of Medicine (1981)

Presentation of CaseA 51-year-old man was admitted to the hospital because of a question of a nasal tumor.He was well until three years earlier, when progressive bilateral nasal obstruction developed. Two years before admission he entered another hospital, where examination showed deviation of the nasal pyramid to the left. The nasal septum was markedly thickened and adherent to the middle turbinates bilaterally. The pharyngeal tonsils were hypertrophied; no cervical lymphadenopathy was noted. A septoplasty was performed; microscopical examination of a biopsy specimen showed chronic inflammation. Several months later the patient began to have recurrent nasal obstruction and discharge. . . .
Meningococcal disease in an ambulance worker
Authors: FM Fusco, V Puro
Journal: Eurosurveillance (2008)

We strongly agree with the authors conclusion that the correct application of droplet precautions, including the use of surgical masks, should always be observed when caring for a suspected case of meningitis. When oxygen supplementation is needed, further precaution measures, such as the use of standard low flow oxygen or placement of bacterial/viral filters should be considered.
The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
Authors: Shengdi Chen, Piu Chan, Shenggang Sun, Haibo Chen, Baorong Zhang, Weidong Le, Chunfeng Liu, Guoguang Peng, Beisha Tang, Lijuan Wang, Yan Cheng, Ming Shao, Zhenguo Liu, Zhenfu Wang, Xiaochun Chen, Mingwei Wang, Xinhua Wan, Huifang Shang, Yiming Liu, Pingyi Xu, Jian Wang, Tao Feng, Xianwen Chen, Xingyue Hu, Anmu Xie, Qin Xiao
Journal: Translational Neurodegeneration (2016)

Parkinson's disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10 years ago, there was lack of standardization for the management of PD in different regions and among different physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese Parkinson's Disease and Movement Disorder Society have published three versions of guidelines for the management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment for PD in China improved. To update the treatment guidelines based on current foreign and domestic practice guidelines and clinical evidence, and to improve the treatment options available to physicians in the management of PD. A variety of treatment recommendations in the treatment guidelines have been proposed, including physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease. The principles of dosage titration should be followed to avoid acute adverse reactions to the drugs, to achieve a satisfactory clinical effect with a low dose and to reduce the incidence of long-term motor complications. Moreover, different treatment strategies should be considered at different stages of the disease. Importantly, treatment guidelines and personalized treatments should be valued equally. A set of treatment recommendations has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China.
Massachusetts Medical Society
Authors: John Figgis Jewett, Donald M. Muirhead
Journal: New England Journal of Medicine (1976)

The prenatal course of a 27-year-old gravida 1 was marked by vaginal staining, a 15 kg weight gain, and fluid retention treated with diuretics. Measurements were not recorded, but the pelvis was labeled "adequate" in a record that did not, however, include the identity, dose or frequency of diuretic medication.At term sudden passage of clear amniotic fluid at about 12:45 a.m. led to admission two hours later in early labor. All vital signs, including the fetal heart beat, were normal, but nurses described the fluid as "slightly meconium stained." In an hour, after preparation and an enema, the fetal . . .
Thromboangiitis Obliterans
Authors: G Rosencrance, T Thistlewaite
Journal: New England Journal of Medicine (1996)

Figure 1. A 35-year-old man who had smoked two packs of cigarettes per day for 20 years presented with necrosis of the ends of the middle finger and the thumb of the left hand. These lesions had been preceded for three to four years by burning sensations and bluish discoloration of the fingers and toes on exposure to cold. Brachial pulses were only slightly diminished, but radial pulses were markedly diminished. The results of all laboratory studies were normal. The patient stopped smoking, and two months later, the fingers were better perfused, though he had lost the distal portions of . . .
Access and outcomes of elderly patients enrolled in managed care
Authors: D. G. Clement
Journal: JAMA (1994)

Objective.  —To determine differences in access to care and medical outcomes for Medicare patients with an acute or a chronic symptom who were enrolled in health maintenance organizations (HMOs) compared with similar fee-for-service (FFS) nonenrollees.  Design.  —A 1990 household telephone survey of Medicare beneficiaries who reported joint pain or chest pain during the previous 12 months.  Sample.  —Stratified random sample of HMO enrollees (n=6476) and comparable sample of FFS Medicare beneficiaries (n=6381).  Access and Outcome Measures.  —Care-seeking behavior, physician visits, diagnostic procedures performed, therapeutic interventions prescribed, follow-up recommended by a physician, and symptom response to treatment.  Results.  —After controlling for demographic factors, health and functional status, and health behavior characteristics, HMO enrollees with joint pain (n=2243) were more likely than nonenrollees (n=2009) to have a physician visit (odds ratio [OR], 1.19; 95% confidence interval [CI], 1.03 to 1.38) and medication prescribed (OR, 1.35; 95% CI, 1.14 to 1.60). Patients with chest pain who were enrolled in HMOs (n=556) were less likely than nonenrollees (n=524) to have a physician visit (OR, 0.50; 95% CI, 0.30 to 0.82). For both joint and chest pain, HMO enrollees were less likely to see a specialist for care, have follow-up recommended, or have their progress monitored. There were no differences in complete elimination of symptoms, but HMO enrollees with continued joint pain reported less symptomatic improvement than nonenrollees (OR, 0.72; 95% CI, 0.59 to 0.86).  Conclusions.  —Reduced utilization of services for patients with specific ambulatory conditions was observed in HMOs with Medicare risk contracts, with less symptomatic improvement in one of the four outcomes studied.  (JAMA. 1994;271:1487-1492)
Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report
Authors: Jia Ruan, Peter Martin, Bijal D. Shah, Stephen J. Schuster, Sonali M. Smith, Richard R Furman, Paul Christos, Amelyn Rodriguez, Louisa Drake, Jakub Svoboda, Jessica Lewis, Orel Katz, Morton Coleman, John P. Leonard
Journal: Blood (2014)